We can’t show the full text here under this license. Use the link below to read it at the source.
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT 2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: R esults from the CVD‐REAL study
Heart attack and stroke rates in people starting SGLT2-inhibitors compared to other diabetes medicines in real-world care
AI simplified
Abstract
The study included 205,160 patients and reported that initiation of sodium-glucose co-transporter-2 inhibitors (SGLT-2i) was associated with lower rates of myocardial infarction and stroke compared to other glucose-lowering drugs.
- There were 1077 myocardial infarction events and 968 stroke events during the follow-up period.
- Initiation of SGLT-2i was associated with a hazard ratio of 0.85 for myocardial infarction compared to other glucose-lowering drugs.
- For stroke, the initiation of SGLT-2i was associated with a hazard ratio of 0.83.
- Statistical significance was found for both outcomes, with P-values of .05 for myocardial infarction and .02 for stroke.
- The findings support previous cardiovascular outcomes trials, indicating potential cardiovascular benefits of SGLT-2i.
AI simplified
Key numbers
0.85
Lower Risk of Myocardial Infarction
Hazard ratio for MI in patients initiating SGLT-2i vs. oGLDs
0.83
Lower Risk of Stroke
Hazard ratio for stroke in patients initiating SGLT-2i vs. oGLDs
205160
205,160 Patients Analyzed
Total number of patients included in the analysis